NO20045233L - Nye krystallinske former av ondansetron, prosesser for deres fremgangsmate, farmasoytiske sammensetninger inneholdende de nye formene og metode for a behandle nausea ved anvendelse - Google Patents

Nye krystallinske former av ondansetron, prosesser for deres fremgangsmate, farmasoytiske sammensetninger inneholdende de nye formene og metode for a behandle nausea ved anvendelse

Info

Publication number
NO20045233L
NO20045233L NO20045233A NO20045233A NO20045233L NO 20045233 L NO20045233 L NO 20045233L NO 20045233 A NO20045233 A NO 20045233A NO 20045233 A NO20045233 A NO 20045233A NO 20045233 L NO20045233 L NO 20045233L
Authority
NO
Norway
Prior art keywords
forms
ondansetron
processes
pharmaceutical compositions
compositions containing
Prior art date
Application number
NO20045233A
Other languages
English (en)
Inventor
Judith Aronhime
Szabolcs Salyi
Csaba Szabo
Sandor Molnar
Erzsebet Meszaros Sos
Tivadar Tamas
Original Assignee
Teva Gyogyszergyar Reszvenytar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Gyogyszergyar Reszvenytar filed Critical Teva Gyogyszergyar Reszvenytar
Publication of NO20045233L publication Critical patent/NO20045233L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ondansetron krystallinske former A og B er anvendbare i behandlingen av kvalme og brekningsfornemmelse. Form B har et unikt høyt smeltepunkt på omtrent 244 ºC, og begge formene er stabile mot termisk indusert polymorf overgang fra 30 ºC opp til deres smeltepunkter.
NO20045233A 2002-04-30 2004-11-29 Nye krystallinske former av ondansetron, prosesser for deres fremgangsmate, farmasoytiske sammensetninger inneholdende de nye formene og metode for a behandle nausea ved anvendelse NO20045233L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37639502P 2002-04-30 2002-04-30
PCT/US2003/013220 WO2003093260A1 (en) 2002-04-30 2003-04-29 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them

Publications (1)

Publication Number Publication Date
NO20045233L true NO20045233L (no) 2005-01-28

Family

ID=29401340

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045233A NO20045233L (no) 2002-04-30 2004-11-29 Nye krystallinske former av ondansetron, prosesser for deres fremgangsmate, farmasoytiske sammensetninger inneholdende de nye formene og metode for a behandle nausea ved anvendelse

Country Status (15)

Country Link
US (1) US20040019093A1 (no)
EP (1) EP1465887A1 (no)
JP (1) JP2005529908A (no)
KR (1) KR20040104677A (no)
CN (1) CN1665803A (no)
AU (1) AU2003223763A1 (no)
CA (1) CA2483532A1 (no)
DE (1) DE20320528U1 (no)
HR (1) HRP20041136A2 (no)
IL (1) IL164905A0 (no)
MX (1) MXPA04010845A (no)
NO (1) NO20045233L (no)
PL (1) PL373192A1 (no)
WO (1) WO2003093260A1 (no)
ZA (1) ZA200408935B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002230935A1 (en) * 2000-10-30 2002-05-15 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
DK1499623T3 (da) * 2002-04-29 2007-10-08 Teva Gyogyszerg Ar Zartkoeruee Fremgangsmåde til fremstilling af 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
ES2238001B1 (es) * 2004-01-21 2006-11-01 Vita Cientifica, S.L. Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
US7288660B2 (en) * 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
CA2664986C (en) 2006-10-02 2015-09-22 Labtec Gesellschaft Fuer Technologische Forschung Und Entwicklung Mbh Non-mucoadhesive film dosage forms
CN103025321A (zh) 2010-03-23 2013-04-03 生物联合制药公司 快速溶解的药物释放系统
EP2377526A1 (en) 2010-03-23 2011-10-19 BioAlliance Pharma Fast dissolving drug delivery systems
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518745D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
HU196598B (en) * 1986-04-25 1988-12-28 Richter Gedeon Vegyeszet Process for producing 1- and/or 8-substituted 2-halogenated ergoline derivatives and pharmaceutics comprising such compounds
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア，インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
CA2106642C (en) * 1992-10-14 2005-08-16 Peter Bod Carbazolone derivatives and process for preparing the same
GB2291005B (en) * 1994-07-08 1998-05-20 Milwaukee Electric Tool Corp Bevel angle adjustment mechanism for a compound mitre saw
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
JP3533519B2 (ja) * 2000-03-09 2004-05-31 株式会社アドバンスト・ディスプレイ Ｔｆｔ基板、フィルムキャリアおよび液晶表示素子の製法
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
DK1499623T3 (da) * 2002-04-29 2007-10-08 Teva Gyogyszerg Ar Zartkoeruee Fremgangsmåde til fremstilling af 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on

Also Published As

Publication number Publication date
ZA200408935B (en) 2006-07-26
AU2003223763A1 (en) 2003-11-17
KR20040104677A (ko) 2004-12-10
HRP20041136A2 (en) 2005-04-30
MXPA04010845A (es) 2005-01-25
IL164905A0 (en) 2005-12-18
DE20320528U1 (de) 2004-09-16
CA2483532A1 (en) 2003-11-13
US20040019093A1 (en) 2004-01-29
JP2005529908A (ja) 2005-10-06
PL373192A1 (en) 2005-08-22
WO2003093260A1 (en) 2003-11-13
EP1465887A1 (en) 2004-10-13
CN1665803A (zh) 2005-09-07

Similar Documents

Publication Publication Date Title
NO20074558L (no) Krystallisasjon og rensing av glykopyrroniumbromid
NO20051118L (no) Fremgangsmate til fremstilling av amorfe og keramiske materialer via smeltespinning
NO20045233L (no) Nye krystallinske former av ondansetron, prosesser for deres fremgangsmate, farmasoytiske sammensetninger inneholdende de nye formene og metode for a behandle nausea ved anvendelse
MX2009007141A (es) Acidos 1-(3-piridinil)pirazol-4-il-aceticos sustituidos, procedimiento para su preparacion y su utilizacion como agentes herbicidas y reguladores del crecimiento de las plantas.
MX2009004351A (es) Anticuerpos anti-htnfalfa cristalinos.
PE20050078A1 (es) Derivados de pirrolidona como inhibidores de maob
MXPA05008705A (es) Derivados de piridina como compuestos fungicidas.
PL345215A1 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
NO20055688L (no) Organiske forbindelser
UA89830C2 (ru) Кристаллическая модификация iv пираклостробина, способы ее получения, композиция для защиты растений и применение
NO20071012L (no) Fremgangsmate for fremstilling av D-erytro-2,2-difluor-2-deoksy-1-oksoribosederivat
PL1670778T3 (pl) Przegrupowane pentanole, sposób ich wytwarzania i ich zastosowanie jako środków hamujących zapalenia
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
BRPI0519292A2 (pt) compostos orgÂnicos
BRPI0416672A (pt) método de produção de uma composição granular contendo lecitina e composição granular contendo lecitina
ATE457982T1 (de) Thiazol-(bi)cycloalkyl-carboxanilide
ATE350123T1 (de) Niedrigtemperaturprozess zum extrahieren der hauptkomponenten aus pflanzen
DK1831239T3 (da) Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-lambda-lacton og nøgle-mellemprodukter til denne fremgangsmåde
NO20064606L (no) Fremgangsmate for a redusere dioksininnholdet av blekejord
DE602006003204D1 (de) Reinigungsverfahren von Moxonidine
NO20092214L (no) Krystallinske former av aryl-substituerte pyrazol-amid forbindelser
MX2008000821A (es) Nuevos derivados de piperidina.
TW200628465A (en) Process for preparing substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
ATE502045T1 (de) Verfahren zur herstellung von perindoprilerbumin
TW200728194A (en) Production process of group 13 metal nitride crystal, production method of semiconductor device, and solution and melt for use in these production process and method

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application